355 related articles for article (PubMed ID: 22685650)
21. The imaging of the hypoxic microenvironment in tumorous tissue using PET/CT and PET/MRI.
Ferda J; Ferdová E; Vítovec M; Glanc D; Mírka H
Eur J Radiol; 2022 Sep; 154():110458. PubMed ID: 35926354
[TBL] [Abstract][Full Text] [Related]
22. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
23. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
24. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
Sathekge M; Maes A; D'Asseler Y; Vorster M; Van de Wiele C
Nucl Med Commun; 2012 Jun; 33(6):581-90. PubMed ID: 22422098
[TBL] [Abstract][Full Text] [Related]
25. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
Takemoto K; Hatano E; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Matsumura K; Zaima M; Toriguchi K; Tanabe K; Kitamura K; Seo S; Taura K; Endo K; Uemoto S; Higashi T
Ann Nucl Med; 2014 May; 28(4):371-80. PubMed ID: 24599824
[TBL] [Abstract][Full Text] [Related]
26. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
27. Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG.
Israel O; Mor M; Gaitini D; Keidar Z; Guralnik L; Engel A; Frenkel A; Bar-Shalom R; Kuten A
J Nucl Med; 2002 Sep; 43(9):1129-36. PubMed ID: 12215549
[TBL] [Abstract][Full Text] [Related]
28. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
29. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
30. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
31. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
32. Role of multi-modality functional imaging in differentiation between benign and malignant thyroid
Shi H; Yuan Z; Yang C; Zhang J; Liu C; Sun J; Ye X
Clin Transl Oncol; 2019 Nov; 21(11):1561-1567. PubMed ID: 30924093
[TBL] [Abstract][Full Text] [Related]
33. Clinical utility of simultaneous whole-body
Chan SC; Yeh CH; Yen TC; Ng SH; Chang JT; Lin CY; Yen-Ming T; Fan KH; Huang BS; Hsu CL; Chang KP; Wang HM; Liao CT
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1297-1308. PubMed ID: 29502310
[TBL] [Abstract][Full Text] [Related]
34. Loco-regional staging of malignant pleural mesothelioma by integrated
Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
[TBL] [Abstract][Full Text] [Related]
36. Dual-tracer PET/CT protocol with [
Wegen S; Weindler J; Voltin CA; van Heek L; Schomäcker K; Fischer T; Marnitz S; Kobe C; Drzezga A; Roth KS
Strahlenther Onkol; 2024 Jan; 200(1):28-38. PubMed ID: 37584717
[TBL] [Abstract][Full Text] [Related]
37. Applications of PET in lung cancer.
Al-Sugair A; Coleman RE
Semin Nucl Med; 1998 Oct; 28(4):303-19. PubMed ID: 9800237
[TBL] [Abstract][Full Text] [Related]
38. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
39. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
40. Metabolic imaging with FDG: a primer.
Delbeke D; Martin WH
Cancer J; 2004; 10(4):201-13. PubMed ID: 15383201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
